Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

D. B. Geffen

Research output: Contribution to journalEditorial

4 Scopus citations
Original languageEnglish
Pages (from-to)1096-1098
Number of pages3
JournalAnnals of Oncology
Issue number5
StatePublished - 1 May 2018
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this